Sol-Gel Technologies (SLGL) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 75.5% versus a loss of 4.1%. Sol-Gel Technologies is the larger company by market cap ($221.0 million vs $208.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | TRDA |
|---|---|---|
| Share price | $67.51 | $5.35 |
| Market cap | $221.03M | $208.31M |
| 1-day change | -6.16% | -4.63% |
| YTD return | +70.73% | -45.43% |
| 1-year return | +75.52% | -4.10% |
| 5-year return | -22.85% | — |
| EPS (TTM) | $-5.61 | $-3.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.97 | $16.45 |
| 52-week low | $28.81 | $5.15 |
| Distance from 52-week high | -31.09% | -67.48% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +125.89% | +255.14% |
| Average volume | 55.30K | 359.01K |
| Shares outstanding | 3.27M | 38.94M |
| Employees | 28 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed TRDA by 79.6 percentage points over the past year.
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
SLGL vs TRDA FAQ
Which is bigger, Sol-Gel Technologies or Entrada Therapeutics?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $221.03M compared with $208.31M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, SLGL or TRDA?
SLGL returned +75.52% over the past 12 months, compared with -4.10% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Sol-Gel Technologies and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.